Why is a payday loan right for you Payday loan 50 up to
Payday loans uk

Equal HCV Treatment Benefits

Posted on April 29, 2015 by in Hep Talk, LifeGuide

LifeGuide [Hep Talk] buy xanax online without prescriptionEqual Treatment Studies show treatment parity among those living with HCV & HCV/HIV by Larry Buhl buy diazepam without prescription ambien for saleA press conference at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) offered two main takeaways: that the new generation of oral direct-acting antiviral agents [...]

Karyn Kaplan

Posted on March 13, 2015 by in Hep Talk, LifeGuide

LifeGuide [Hep Talk] Planting Seeds An activist shares grassroots strategies for making HCV treatment available worldwide by Larry Buhl Hepatitis treatment advocates identify three significant barriers to eradicating hepatitis C virus (HCV) in low-and middle-income countries: the lack of data necessary for development of policies, programs, and resource allocation; criminalization of people who inject drugs [...]

Is Mass HCV Screening the Best Approach?

Posted on February 23, 2015 by in Hep Talk, LifeGuide

LifeGuide [Hep Talk] Calling All Boomers New analysis questions the need for mass HCV screening by Larry Buhl In 2012, the U.S. Centers for Disease Control and Prevention (CDC) recommended screening everyone born between 1945 and 1965—the so-called Baby Boom generation—for the hepatitis C virus (HCV) whether or not they think they were exposed to [...]

HCV Institute

Posted on December 27, 2014 by in Hep Talk, LifeGuide

LifeGuide [Hep Talk] Mirror Image With a new institute for HCV, AAHIVM shows parallels between treating it and HIV by Larry Buhl More HIV providers are treating hepatitis C than ever before—provided the private insurers and public payers permit it. That’s one reason the American Academy of HIV Medicine (AAHIVM) has created an Institute for [...]

HCV Care Cascade

Posted on November 6, 2014 by in Hep Talk, LifeGuide

LifeGuide [Hep Talk] Breaking the Bottlenecks A new focus on cascade of care seeks to expand screening & treatment by Larry Buhl Originally coined to describe the continuum of care—and the gaps in care—for people with HIV, the term cascade of care is now used for hepatitis C and other diseases. The cascade and number [...]

HCV Behind Bars: Part I

Posted on September 9, 2014 by in Hep Talk, LifeGuide

LifeGuide [Hep Talk] Treatment Behind Bars Part I: Who pays for direct-acting antiretrovirals in prisons? by Larry Buhl The new class of direct-acting antiretrovirals (DAAs) that have revolutionized treatment of hep C have greatly boosted the chances of recovery. The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America [...]

HCV & Underreporting

Posted on May 13, 2014 by in Hep Talk, LifeGuide

By the Numbers While HCV prevalence is down, the rate of morbidity may be going up by Larry Buhl New data on the prevalence of hepatitis C virus (HCV) in the U.S. shows that, with a “silent epidemic,” it’s hard to get accurate numbers. A disease that often has no symptoms, and that hits populations [...]

Coffee & HCV

Posted on March 6, 2014 by in Hep Talk, LifeGuide

Coffee Talk Two studies shed light on HCV prevention & treatment by Larry Buhl A study on the long-term infectiousness of the hepatitis C virus (HCV) has implications for healthcare workers, IV drug users, and tattoo artists, while another study shows the benefits of coffee and tea on liver inflammation in chronic hepatitis C patients. [...]

HCV Serosorting

Posted on January 24, 2014 by in Hep Talk, LifeGuide

Testing, Testing Serosorting is common for IV drug users who know their HCV status by Larry Buhl A new study shows IV drug users who know they carry the hepatitis C virus are likely to consider their serostatus when deciding whether and with whom to share injection equipment. The results, published in the December 15, [...]

Direct-Acting Antivirals & HCV

Posted on December 31, 2013 by in Hep Talk, LifeGuide

Hep Talk by Larry Buhl Two Agents New direct-acting antivirals cross a major hurdle                       The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) in October gave unanimous recommendations for approval of two next-generation direct-acting antivirals (DAAs) for hepatitis C, Janssen’s [...]